These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

229 related items for PubMed ID: 32976551

  • 1. Effect of hydroxyurea exposure before puberty on sperm parameters in males with sickle cell disease.
    Joseph L, Jean C, Manceau S, Chalas C, Arnaud C, Kamdem A, Pondarré C, Habibi A, Bernaudin F, Allali S, de Montalembert M, Boutonnat-Faucher B, Arlet JB, Koehl B, Cavazzana M, Ribeil JA, Lionnet F, Berthaut I, Brousse V.
    Blood; 2021 Feb 11; 137(6):826-829. PubMed ID: 32976551
    [Abstract] [Full Text] [Related]

  • 2. Effect of hydroxyurea on sperm count, motility and morphology in adult men with sickle cell or myeloproliferative disease.
    Grigg A.
    Intern Med J; 2007 Mar 11; 37(3):190-2. PubMed ID: 17316339
    [Abstract] [Full Text] [Related]

  • 3. Adverse effects of a clinically relevant dose of hydroxyurea used for the treatment of sickle cell disease on male fertility endpoints.
    Jones KM, Niaz MS, Brooks CM, Roberson SI, Aguinaga MP, Hills ER, Rice VM, Bourne P, Bruce D, Archibong AE.
    Int J Environ Res Public Health; 2009 Mar 11; 6(3):1124-44. PubMed ID: 19440437
    [Abstract] [Full Text] [Related]

  • 4. Hydroxyurea therapy contributes to infertility in adult men with sickle cell disease: a review.
    DeBaun MR.
    Expert Rev Hematol; 2014 Dec 11; 7(6):767-73. PubMed ID: 25242414
    [Abstract] [Full Text] [Related]

  • 5. Effects of hydroxyurea on fertility in male and female sickle cell disease patients. A systemic review and meta-analysis.
    Sewaralthahab S, Alsubki LA, Alhrabi MS, Alsultan A.
    PLoS One; 2024 Dec 11; 19(6):e0304241. PubMed ID: 38848387
    [Abstract] [Full Text] [Related]

  • 6. Bone marrow transplantation or hydroxyurea for sickle cell anemia: long-term effects on semen variables and hormone profiles.
    Lukusa AK, Vermylen C, Vanabelle B, Curaba M, Brichard B, Chantrain C, Dupont S, Ferrant A, Wyns C.
    Pediatr Hematol Oncol; 2009 Jun 11; 26(4):186-94. PubMed ID: 19437321
    [Abstract] [Full Text] [Related]

  • 7. Study of Seminal Fluid Parameters and Fertility of Male Sickle Cell Disease Patients and Potential Impact of Hydroxyurea Treatment.
    Sahoo LK, Kullu BK, Patel S, Patel NK, Rout P, Purohit P, Meher S.
    J Assoc Physicians India; 2017 Jun 11; 65(6):22-25. PubMed ID: 28782309
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Chronic Administration of Hydroxyurea (HU) Benefits Caucasian Patients with Sickle-Beta Thalassemia.
    Di Maggio R, Hsieh MM, Zhao X, Calvaruso G, Rigano P, Renda D, Tisdale JF, Maggio A.
    Int J Mol Sci; 2018 Feb 28; 19(3):. PubMed ID: 29495591
    [Abstract] [Full Text] [Related]

  • 11. Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial.
    Alvarez O, Yovetich NA, Scott JP, Owen W, Miller ST, Schultz W, Lockhart A, Aygun B, Flanagan J, Bonner M, Mueller BU, Ware RE, Investigators of the Stroke With Transfusions Changing to Hydroxyurea Clinical Trial (SWiTCH).
    Am J Hematol; 2013 Nov 28; 88(11):932-8. PubMed ID: 23861242
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Five years of experience with hydroxyurea in children and young adults with sickle cell disease.
    Ferster A, Tahriri P, Vermylen C, Sturbois G, Corazza F, Fondu P, Devalck C, Dresse MF, Feremans W, Hunninck K, Toppet M, Philippet P, Van Geet C, Sariban E.
    Blood; 2001 Jun 01; 97(11):3628-32. PubMed ID: 11369660
    [Abstract] [Full Text] [Related]

  • 15. Adverse effect of hydroxyurea on spermatogenesis in patients with sickle cell anemia after 6 months of treatment.
    Berthaut I, Bachir D, Kotti S, Chalas C, Stankovic K, Eustache F, Ravel C, Habibi A, Brailly-Tabard S, Lévy-Dutel L, Bleibtreu A, Simon T, Galactéros F, Lionnet F, Mandelbaum J.
    Blood; 2017 Nov 23; 130(21):2354-2356. PubMed ID: 28972009
    [No Abstract] [Full Text] [Related]

  • 16. Perception to hydroxyurea therapy in patients with sickle cell disease: Report from 3 centers.
    Korubo KI, Onodingene NM, Okoye HC, Omunakwe HE.
    Ann Afr Med; 2021 Nov 23; 20(2):127-131. PubMed ID: 34213480
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS).
    Voskaridou E, Christoulas D, Bilalis A, Plata E, Varvagiannis K, Stamatopoulos G, Sinopoulou K, Balassopoulou A, Loukopoulos D, Terpos E.
    Blood; 2010 Mar 25; 115(12):2354-63. PubMed ID: 19903897
    [Abstract] [Full Text] [Related]

  • 19. Real-life experience with hydroxyurea in sickle cell disease: A multicenter study in a cohort of patients with heterogeneous descent.
    Rigano P, De Franceschi L, Sainati L, Piga A, Piel FB, Cappellini MD, Fidone C, Masera N, Palazzi G, Gianesin B, Forni GL, Italian Multicenter Study of Hydroxyurea in Sickle Cell Anemia Investigators.
    Blood Cells Mol Dis; 2018 Mar 25; 69():82-89. PubMed ID: 29107441
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.